Clinical trial · Interventional
Immunogenicity and Clinical Efficacy of 20-valent Pneumococcal Conjugate Vaccine (PCV20) in Lymphoma Survivors After Treatment With Anti-CD20 Therapy
NCT06049134CI-TRIAL-00104965active not recruitingPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 16, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260916-000001
Summary
Brief summary (as posted)
To compare the effects of a pneumococcal vaccine called PCV20 when given as a single dose versus a boosted regimen to patients who previously received anti-CD20 therapy as treatment for B cell lymphoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| PCV20 | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Arm Group A (PCV20)
- description
- Participants will receive 1 dose of the vaccine
- interventionNames
- Biological: PCV20
- type
- EXPERIMENTAL
- label
- Arm Group B (PCV20)
- description
- Participants will receive 2 doses of the vaccine
- interventionNames
- Biological: PCV20
Primary outcomes (1)
- measure
- Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
- timeFrame
- through study completion; an average of 1 year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients who have a history of non-Hodgkin B-cell lymphoma and whose disease has been in remission for at least 1 year. 2. Patients who received any anti-CD20 therapy at any time during their treatment for B-cell lymphoma. 3. Patients who are at least 18 years of age. 4. Patients who can provide consent; no legal authorized representative will be able to provide consent on a patient's behalf. Exclusion Criteria: 1. Patients who have received cellular therapy, including chimeric antigen receptor T-cell therapy or any type of hematopoietic cell transplantation. 2. Patients who have received PCV or pneumococcal polysaccharide vaccine within 5 years of screening for enrollment. 3. Patients who are unable to attend follow-up appointments at designated times at MD Anderson. 4. Any vulnerable population patient ((children, pregnant women, cognitively impaired adults, or prisoners)
References
Publications (0)
Data not yet available
No reference posted for this study.